Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Pulsenmore accelerates U.S. commercialization with partnerships and funding

Aug 31, 2026, 7:05 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Material US commercial momentum plus first US agreements, plus meaningful cash runway from private placement, reduce near-term risk and support a positive read on PLSM. Dilution risk exists from warrants and higher opex, but liquidity and partnerships can drive multiple expansion if US revenue accelerates.

AI summary

What happened, with direct paths to the underlying reporting

Pulsenmore reports a transformative first half of 2026, accelerating U.S. commercialization after FDA clearance. The company signed its first U.S. commercial agreements (CFFM, TLC Perinatal), sold 4,265 ES units and 300 FC units, and closed a private placement that raised roughly NIS 22.5 million (~$7.5 million), lifting cash toward 70 million NIS. Israeli AI grants and manufacturing expansion bolster longer-term growth.

US commercialization accelerates after FDA clearance; first US agreements signed.
H1 2026 revenue 6.1m NIS; 4,265 ES units sold.
Private placement raises ~NIS 22.5m; cash on hand ~70m NIS.
Partnerships with Ouma Health; Lis Ichilov integration expands care.
FDA and Israel MOH clear ES Tera; manufacturing expansion planned.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.